Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany by unknown
ORIGINAL PAPER
Cost-effectiveness of ticagrelor versus clopidogrel
for the prevention of atherothrombotic events in adult
patients with acute coronary syndrome in Germany
Ulrike Theidel • Christian Asseburg •
Evangelos Giannitsis • Hugo Katus
Received: 1 November 2012 / Accepted: 18 February 2013 / Published online: 9 March 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract The aim of this health economic analysis was
to compare the cost-effectiveness of ticagrelor versus
clopidogrel within the German health care system. A two-
part decision model was adapted to compare treatment with
ticagrelor or clopidogrel in a low-dose acetylsalicylic acid
(ASA) cohort (B150 mg) for all ACS patients and subtypes
NSTEMI/IA and STEMI. A decision-tree approach was
chosen for the first year after initial hospitalization based
on trial observations from a subgroup of the PLATO study.
Subsequent years were estimated by a Markov model.
Following a macro-costing approach, costs were based on
official tariffs and published literature. Extensive sensitiv-
ity analyses were performed to test the robustness of the
model. One-year treatment with ticagrelor is associated
with an estimated 0.1796 life-years gained (LYG) and
gained 0.1570 quality-adjusted life-years (QALY),
respectively, over the lifetime horizon. Overall average
cost with ticagrelor is estimated to be EUR 11,815 vs. EUR
11,387 with generic clopidogrel over a lifetime horizon.
The incremental cost-effectiveness ratio (ICER) was EUR
2,385 per LYG (EUR 2,728 per QALY). Comparing
ticagrelor with Plavix or the lowest priced generic
clopidogrel, ICER ranges from dominant to EUR 3,118 per
LYG (EUR 3,567 per QALY). These findings are robust
under various additional sensitivity analyses. Hence,
12 months of ACS treatment using ticagrelor/ASA instead
of clopidogrel/ASA may offer a cost-effective therapeutic
option, even when the generic price for clopidogrel is
employed.
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Introduction
In Germany, every year more than 400,000 patients are
admitted to hospitals for suspected acute coronary syn-
drome (ACS) [1]. Cardiovascular (CV) disease is the
leading cause of mortality in Germany, with more than
60,000 deaths due to acute or recurrent myocardial
infarction [2]. Despite high resource use and services
supplied to these patients mortality rates of 30 % or higher
have been reported 1 year post-ACS [3–5]. Therefore, the
reduction of CV event rates, particularly CV and all-cause
mortality, still remains a key priority. Effective strategies
to reduce CV mortality include reduction of pre-hospital
and hospital delays, preferred use of an appropriately timed
invasive strategy with percutaneous coronary intervention
(PCI) and coronary stenting, use of more potent anti-platelet
and anti-thrombin-inducing drugs, and comprehensive
secondary prevention including utilization of acetylcholines-
terase (ACE)-inhibitors, beta-blockers and statins. A 10 %
increase of guideline adherence has been shown to reduce in-
hospital mortality rates by 10 % [6] which makes this a
desirable task.
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Dual therapy with acetylsalicylic acid (ASA) and clop-
idogrel is a standard treatment option in patients with ACS.
Treatment is recommended to start as early as possible and
to be continued for 12 months post-ACS [7]. The efficacy
of clopidogrel, a second generation thienopyridine that
blocks the adenosine diphosphate (ADP) receptor on
platelets is hampered by a slow and variable transformation
of the prodrug to the active metabolite, modest and variable
platelet inhibition, an increased risk of bleeding and an
increased risk of stent thrombosis and myocardial infarc-
tion in patients with a poor response. Ticagrelor, a novel
reversible and direct-acting oral antagonist of the adeno-
sine diphosphate receptor P2Y12, showed faster, higher,
and more consistent P2Y12 inhibition than clopidogrel.
The pivotal PLATelet inhibition and patient outcomes
(PLATO) phase III trial showed that ticagrelor was supe-
rior to clopidogrel for the prevention of CV death, myo-
cardial infarction (MI), or stroke (9.8 vs. 11.7 % at
12 months; 16 % RRR; 95 % CI, 0.77–0.92; p \ 0.001)
without a significant increase of major bleeding (11.6 vs.
11.2 %, p = 0.43). The primary efficacy endpoint was
driven by CV death (4.0 vs. 5.1 %, p = 0.001) and myo-
cardial infarction (MI) (5.8 vs. 6.9 %, p = 0.005) with no
difference in stroke (1.5 vs. 1.3 %, p = 0.22). Secondary
safety endpoints show a significant increase in non-CABG-
related spontaneous major bleedings (4.5 vs. 3.8 %,
p = 0.03) and episodes of any dyspnea (13.8 vs. 7.8 %) and
more bradycardic events (4.7 vs. 4.4 %) in a broad popu-
lation of patients with ACS. There was no significant dif-
ference in the incidence of fatal bleedings (p = 0.66) [8].
In the PLATO study some patients received higher
dosages of ASA, especially in centers outside the EU. In a
pre-specified subgroup analysis, a significant interaction
between treatment and region (p = 0.045) was shown [8].
In a treatment-by-region analysis Mahaffey et al. [9]
quantified how much of the regional interaction could be
explained by patient characteristics and concomitant
treatments, including aspirin maintenance therapy. Adjus-
ted analyses showed that ticagrelor was associated with
better outcomes compared with clopidogrel in patients
taking low-dose maintenance aspirin, with statistical
superiority in the rest of the world and similar outcomes in
the US cohort. Thus, the aspirin maintenance dose seems to
offer a possible explanation for regional differences.
In Germany, the recommended dosage of ASA in com-
bination with ticagrelor ranges from 75 up to 150 mg per day
[10]. Addressing that issue and according to the requirements
of the recently implemented benefit assessment regulation for
new drugs (Arzneimittelmarktneuordnungsgesetz, AM-
NOG), a subgroup analysis was performed with the PLATO
results evaluating the subset of patients in the study cohort
receiving B150 mg ASA (ASA low-dose cohort). Data were
presented as part of the benefit assessment of ticagrelor to the
Federal Joint Committee (Gemeinsamer Bundesausschuss,
G-BA) in Germany [11] and showed more favorable results
than for the overall cohort: composite endpoint (7.9 vs.
10.2 % at 12 months; 22 % RRR; 95 % CI, 0.70–0.87;
p \ 0.0001), also driven by CV death (3.1 vs. 4.4 %; 29 %
RRR; CI 95 %, 0.60–0.84; p \ 0.0001) and MI (4.8 vs.
6.1 %, 21 % RRR; CI 95 %, 0.69–0.91, p = 0.0008). No
differences in stroke were found (1.3 vs. 1.1 %; p = 0.2669).
Secondary safety endpoints showed no significant increase in
non-CABG-related spontaneous major bleedings (4.3 vs.
3.6 %, p = 0.06). Incidence of fatal bleedings also reached
no significance (p = 0.99) (for more details see ‘‘Supple-
mentary Material’’).
The published benefit assessment for ticagrelor [12]
reported an added clinical benefit for patients without ST-
segment elevation (NSTEMI) and unstable angina (UA).
The main inclusion criteria for patients with ST-segment
elevation (STEMI) of the PLATO study was a planned
PCI. In this population, the comparator for the benefit
assessment was prasugrel according to the recommendation
of G-BA. Based on an indirect comparison with prasugrel,
the assessment of the Institute for Quality and Efficiency in
Health Care (Institut fu¨r Qualita¨t und Wirtschaftlichkeit im
Gesundheitswesen, IQWiG) came to the conclusion that
not enough evidence versus prasugrel could be presented
by the dossier for these patients.
Aim of the present study was to assess the cost-effec-
tiveness of ticagrelor over lifetime with a treatment period
of 12 months compared to clopidogrel according to the
requirements of the benefit assessment (ASA low-dose
cohort). Cost-effectiveness was evaluated for ACS sub-
types (NSTEMI/UA and STEMI) and, to get a complete




PLATO (ClinicalTrials.gov identifier NCT00391872) was
an international, prospective, randomized, double-blind,
double dummy, event-driven trial in patients hospitalized
for NSTEMI that was managed invasively or medically, or
STEMI scheduled for primary PCI strategy. Details of the
design, population, and outcome measures for the trial and
for pre-specified subgroups have been published elsewhere
[8]. Patients were randomized to receive either ticagrelor or
clopidogrel within 24 h of onset of the most recent cardiac
ischemic symptoms and before PCI. Ticagrelor-treated
patients received a 180 mg loading dose followed by a
maintenance dose of 90 mg BID. Clopidogrel-treated
patients who had not already received a loading dose of
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open-label clopidogrel or who had not been taking clopi-
dogrel or ticlopidine for [5 days before randomization
received a 300-mg loading dose followed by 75 mg QD.
The remaining patients received 75 mg clopidogrel as their
first dose. Patients undergoing PCI received an additional
90 mg dose of ticagrelor/placebo at procedures[24 h after
randomization and, at the discretion of the investigator, an
additional 300 mg clopidogrel/placebo at any time relative
to randomization. All patients received 75–100 mg/day
acetylsalicylic acid unless intolerant. For patients not pre-
viously receiving ASA, a loading dose of 325 mg was
preferred (although a dose of 160–500 mg was allowed).
After stent placement, an ASA dose up to 325 mg/day was
allowed for up to 6 months, and a lower dose was used
thereafter. Outpatient visits were scheduled up to
12 months, with a safety follow-up visit 1 month after end
of treatment. The randomized treatment was scheduled to
continue for 12 months, but patients left the study at their
6- or 9-month visit if the targeted number of 1,780 primary
endpoint events had occurred by that time.
Cost-effectiveness study
Based on clinical data derived from the PLATO study, a
two-part decision-analytic model, comprising a 1-year
decision tree and a long-term Markov model, was adapted
to estimate lifetime costs as well as health outcomes. The
model structure was informed by earlier studies in this
field. The main difference to the already existing multi-
national model [13, 14] is the used macro-costing approach
to generate the cost data. The primary health outcomes are
mean cost and life-years gained (LYG) of treating ACS
patients for 1 year with ticagrelor plus ASA compared with
clopidogrel plus ASA. In addition to LYs, quality-adjusted
life-years (QALYs) are estimated in the model secondarily.
Possible events in the model are ‘‘overall death’’, ‘‘myo-
cardial infarction’’, and ‘‘stroke’’. Adverse and subsequent
events were not explicitly included in the analysis. Both
items implicitly are still considered in the QALY analysis
and via the inclusion of associated cost. Subgroup analysis
was done for NSTEMI/UA and STEMI. After a non-fatal
event, no further events were incorporated as these events
occurred very seldom during the clinical trial.
The time horizon within a Markov model is always
determined by the disease and the chosen perspective of
evaluation. Even if the therapy of dual platelet inhibition is
limited to the first 12 months after ACS index hospital-
ization, long-term consequences of a chronic disease will
continue to have an impact throughout the remaining
lifetime. As mentioned above, ACS is an event that chan-
ges the prognosis of a patient permanently for the entire
life. Thus, in the base case the model is evaluated over
lifetime and hence extrapolates beyond the study duration
of the pivotal study. First year results were analyzed solely
with a decision-tree approach, i.e., for the first year the
study data of the phase III study was used.
Treatment with ticagrelor or clopidogrel is recom-
mended only for 12 months. Therefore, the patients receive
the drug therapy in both arms only in the first year. In the
second step for the long-term analysis, a Markov model
approach was chosen with a cycle length of 12 months. As
no long-term data are available after the first year of
treatment, the conservative assumption was made that no
relevant differences exist regarding the efficacy between
both alternatives. Starting the model with the Markov
approach with the second year the only difference between
both model arms arises from the different distribution of
patients in the different Markov states after the first year.
Moreover, transition probabilities of clinical events are
assumed to be independent of treatment arm in the long-
term model; Fig. 1 shows the model schematically.
The Markov health states correspond to the clinical
endpoints in the PLATO study: overall mortality, myo-
cardial infarction, and stroke. Patients who did not have an
event during the first year will start in the Markov model in
the state ‘‘no event’’. These patients may suffer a fatal
myocardial infarction (MI) or stroke in every subsequent
year (arrow 3 in Fig. 1) and may also transit to a ‘‘non-fatal
MI’’ (arrow 1) or ‘‘non-fatal stroke’’ (arrow 2). Annual
probabilities for these transitions were estimated by
extrapolating the Weibull regression models corresponding
to the clopidogrel arm of the PLATO study to obtain the
probability of events during year 2, conditional on no event
in year 1. Based on a comparison of the predicted pro-
portion of patients with events and the observed Kaplan–
Meier estimates from the PLATO study, the Weibull model
was found to provide the best fit with the clinical data.
These transition probabilities were assumed to be constant
beyond year 2 in both arms. Whenever a fatal event occurs,
a patient passes to the absorbing state of ‘‘Death’’. Mor-
tality due to non-cardiovascular causes (also part of arrow
3) was estimated using the current German mortality tables,
and is presumed to be known with certainty. The overall
mortality was estimated conservatively and no extraction
was made to exclude the mortality due to cardiovascular
causes from the German standard mortality. Hence, in the
base case mortality is overestimated.
Additional mortality risk due to non-fatal myocardial
infarction or non-fatal stroke in the long-term model
(arrows 4–7) and risk of other mortality (arrow 3) are
parameterized by inflating mortality through hazard ratios
(HR), parameterized using log-normal distributions. In the
base case, assumptions regarding these hazard ratios
relating to post-event mortality were made based on data
from publications [15] and Federal Health Monitoring
(Gesundheitsberichterstattung des Bundes) [16] (HR ‘‘no
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event’’: 1/HR ‘‘non-fatal MI’’ first year: 1.6/HR ‘‘non-fatal
MI’’ second and subsequent years: 1.4/HR ‘‘non-fatal
stroke’’ first year: 3.23/HR ‘‘non-fatal stroke’’ second and
subsequent years: 1.5). To compare the impact of different
assumptions regarding these hazard ratios, hazards pro-
vided from the Global model were used in a sensitivity
analysis (HR ‘‘no event’’: 2/HR ‘‘non-fatal MI’’ first year:
6/HR ‘‘non-fatal MI’’ second and subsequent years: 3/HR
‘‘non-fatal stroke’’ first year: 7.43/HR ‘‘non-fatal stroke’’
second and subsequent years: 3) [14].
Several validation rounds were conducted, which
included testing the model for internal validity and revising
programming errors.
Various sensitivity analyses were carried out to test the
robustness of the results. For the probabilistic sensitivity
analysis of the clinical effects and quality of life parameters,
10,000 iterations were conducted. Clinical efficacy data for
the first year were represented by Weibull regression models
that summarize the effect size and temporal distributions of
the PLATO study events and associated uncertainty. This
approach automatically includes the consideration of any
correlations between effect size and ‘‘base line’’, and was
chosen because it can best reflect any uncertainties and their
relations to each other. Cost data are considered as known
with certainty, no matter from which source they are derived.
Robustness to cost assumptions was tested in univariate
sensitivity analyses.
The primary endpoints of the cost-effectiveness model
are absolute and incremental LYG, in relation to overall
therapy costs. For the subgroups NSTEMI/UA and STEMI
the same model structure and sensitivity analyses were
used. Only clinical and cost data were modified (see the
following section).
Model inputs
Transition probabilities for the disease conditions are based
on PLATO results. For each study outcome, a Weibull
parametric survival regression was fitted to the patient-
level data, a statistical approach that respects the trial
randomization scheme. The published hazard ratio deter-
mined within the scope of the semi-parametric Cox pro-
portional hazard model, cannot be used directly for the
modeling approach. For subsequent years, no data were
available. Therefore, conservative assumptions were made
with respect to the occurrence probabilities. The residual
mortality was estimated on the basis of current German
mortality tables.
In terms of quality of life, the decision tree represents
the data as collected in the PLATO study. The long-term
model contains quality of life as an average value appro-
priate to the age and deductions which illustrate morbidi-
ties (MI and stroke). All data are presented in Tables 1, 2
and 3.
Fig. 1 Model structure used for all subgroup analyses
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The calculation of health expenses is a challenge as there is
no detailed information on health costs for treatment of ACS
in Germany available from official sources. A study by Taylor
et al. [17] indicates that costs amounted to approximately
EUR 3.3 billion in 2004. The Federal Health Monitoring [18]
reported direct costs for acute and recurrent myocardial
infarctions of around EUR 1.8 billion in 2008. Looking at the
costs of ACS treatment per capita the statutory health insur-
ance (Gesetzliche Krankenversicherung, GKV) states annual
costs between EUR 8,280 and EUR 11,067 per patient in
Germany. The majority of the expenses are due to hospital-
ization (ranging from 77 to 83 %). Furthermore, disability,
invalidity, or premature death due to acute myocardial
infarction result in a loss of 1.6 % of all work years in 2006
(i.e., 64,000 person-years) affecting predominantly men
(approximately 87 %). Thus, the loss of 127,000 work years
by ischemic heart diseases translates into a national economic
loss to society of approx. EUR 4.3 billion [4]. Therefore and
while the cost data in particular cannot be taken from multi-
national randomized controlled trials (RCTs), a macro-cost-
ing approach was chosen for this analysis to generate cost data
from other sources [19].
The PLATO-associated health economic substudy [20]
provides initial resource use and cost structures via a
micro-costing approach, but it does not completely cover
the resource use in the context or from the perspective of
the German statutory health insurance [21].
Hence, a macro-costing approach was chosen and
additional relevant cost data for events were identified from
publicly accessible databases and the literature. Unit cost
inputs were selected on the basis of best available evidence
and are standardized (inflation-adjusted) to the year 2009.
To evaluate the cost-effectiveness for both treatments, the
focus of interest is on costs or savings occurring after the
initiation of a chosen therapy. For this, in the underlying
macro-costing approach costs for the index hospitalization
were excluded from the analysis as these costs are covered
by lump sum payment (diagnosis-related group, DRG)
regardless of the initiation of any pharmacological
treatment.
For acute hospitalization events, data from the official
German DRG browser were used. In reality, depending on
the disease history of a patient, existing co-morbidities and
the specific kind, of event patients will be classified into
Table 1 Model input
parameters (overall ACS patient
population B150 mg ASA)
Ticagrelor Clopidogrel Source
Model parameters during the first year
Probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.041 0.049 Weibull regression
Non-fatal stroke 0.008 0.008 Weibull regression
Death 0.036 0.050 Weibull regression
Utility values
No event 0.875 0.878 PLATO data
Non-fatal myocardial infarction 0.817 0.801 PLATO data
Non-fatal stroke 0.748 0.720 PLATO data
Death 0.259 0.249 PLATO data
Model parameters Markov model Common to both treatment arms
Annual probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.021 Extrapolation from Weibull regression
Non-fatal stroke 0.004 Extrapolation from Weibull regression
Fatal CV event 0.019 Extrapolation from Weibull regression
Observed utility in the PLATO trial
No event (age 60–69) 0.877 PLATO data
No event (age 70–79) 0.838 PLATO data
No event (age 80?) 0.773 PLATO data
Utility decrements
Year 1 after a stroke 0.143 PLATO data
Year 2? after a stroke 0.143 PLATO data
Year 1 after a myocardial infarction 0.068 PLATO data
Year 2? after a myocardial
infarction
0.068 PLATO data
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different DRGs. Therefore, relevant DRGs were identified
in the browser using the corresponding ICD-10 codes
resulting in a weighted cost average per case observed in the
PLATO data. Information for time after hospitalization was
focused on the clinical pathways. Costs of cardiological
rehabilitation were included, comprising outpatient as well
as inpatient resources subsequent to hospital discharge,
followed by visits to general practitioner (GP) or visits to a
cardiologist and nursing care if needed. Indirect costs such
as sick leave or early retirement were not incorporated into
the base case model as these costs are not relevant from the
perspective of the statutory health insurance. Costs for
management of adverse events are covered by lump sum
payment for in-hospital or outpatient treatment. Therefore,
no extra costs for adverse events were included.
The costs for death were reported by federal statistics.
An average amount of EUR 8,650 [22] was applied to the
distribution of death due to cardiovascular or other causes
as observed in PLATO. In the base case scenario for
patients in the ‘‘no event’’—state drug costs only and no
other health-care costs were included in both arms. The
costs of medication in the base case scenario were
calculated using pharmacy retail prices (public prices)
without any discounts. The daily therapy costs (DTC) for
ticagrelor are EUR 2.90 (EUR 147.57 per 100 tablets) [23].
For clopidogrel, a DTC of EUR 0.72 (average generic
price) was used in the base case as well as EUR 0.35 for
lowest generic and EUR 2.38 for Plavix in the sensitivity
analyses [23]. All prices were calculated excluding com-
pulsory rebates [23] (Table 4).
Subgroup-specific cost data could be generated for the
MI state only. All other MI cost and cost for stroke and
death were assumed to be equal (Table 5).
In addition, indirect costs (early retirement and work
disability) as well as additional costs for no primary
(study) event were incorporated in a sensitivity analysis:
EUR 2,744 [30] for a myocardial infarction in the first
year, EUR 4,417 [26, 30, 31] for a stroke in the first and
EUR 4,336 [29] in the following years.
In accordance to current guideline (Hannoveraner
Konsens [32]) all costs and benefit components were sub-
ject to a discount rate of 3 % in the base case scenario.
Different discount rates were tested in the sensitivity
analysis.




Model parameters during the first year
Probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.052 0.058 Weibull regression
Non-fatal stroke 0.008 0.009 Weibull regression
Death 0.038 0.050 Weibull regression
Utility values
No event 0.864 0.863 PLATO data
Non-fatal myocardial infarction 0.794 0.777 PLATO data
Non-fatal stroke 0.736 0.677 PLATO data
Death 0.275 0.235 PLATO data
Model parameters Markov model Common to both treatment arms
Annual probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.024 Extrapolation from Weibull regression
Non-fatal stroke 0.004 Extrapolation from Weibull regression
Fatal CV event 0.023 Extrapolation from Weibull regression
Observed utility in the PLATO trial
No event (age 60–69) 0.864 PLATO data
No event (age 70–79) 0.826 PLATO data
No event (age 80?) 0.762 PLATO data
Utility decrements
Year 1 after a stroke 0.157 PLATO data
Year 2? after a stroke 0.157 PLATO data
Year 1 after a myocardial infarction 0.078 PLATO data
Year 2? after a myocardial
infarction
0.078 PLATO data
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Results
On the basis of the described model, it can be expected that
the total average costs of therapy with ticagrelor over the
entire remaining lifetime in the base case scenario will
accrue to an average of EUR 11,815, as compared to
EUR 11,387 with generic clopidogrel (average generic
price). This leads to incremental costs of EUR 428. Driven
by the data from the PLATO study [8], it is expected that
20 clinical events can be prevented per 1,000 ACS patients
in the first year. Translated to the entire lifespan, this leads
to 0.1796 years of LYG (0.1570 QALYs). The costs per
life-year gained are, therefore, EUR 2,385 (EUR 2,728)
in the base case scenario. For detailed results see Table 6.
These results are based on the conservative assumption
that there is no incremental clinical benefit from ticagrelor
vs. clopidogrel beyond the first year of treatment.
An overview of the results from the various scenarios
explored with the model is provided in Fig. 2. The negative
ICER shown for the sensitivity analysis regarding the price
Table 3 Model input
parameters (STEMI B150 mg
ASA)
Ticagrelor Clopidogrel Source
Model parameters during the first year
Probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.026 0.038 Weibull regression
Non-fatal stroke 0.008 0.007 Weibull regression
Death 0.032 0.046 Weibull regression
Utility values
No event 0.891 0.899 PLATO data
Non-fatal myocardial infarction 0.879 0.855 PLATO data
Non-fatal stroke 0.763 0.833 PLATO data
Death 0.228 0.281 PLATO data
Model parameters Markov model Common to both treatment arms
Annual probability of the endpoint (mean value)
Non-fatal myocardial infarction 0.016 Extrapolation from Weibull regression
Non-fatal stroke 0.003 Extrapolation from Weibull regression
Fatal CV event 0.015 Extrapolation from Weibull regression
Observed utility in the PLATO trial
No event (age 60–69) 0.895 PLATO data
No event (age 70–79) 0.856 PLATO data
No event (age 80?) 0.789 PLATO data
Utility decrements
Year 1 after a stroke 0.097 PLATO data
Year 2? after a stroke 0.097 PLATO data
Year 1 after a myocardial infarction 0.028 PLATO data
Year 2? after a myocardial
infarction
0.028 PLATO data





First year in EUR
Acute hospitalization
(incl. early rehabilitation)
4,226 [22] 9,791 [22]
Further hospitalization 2,601 [23] 1,063 [24]
Rehabilitation 1,757 [25] 1,610 [24]
Doctor’s visit/nursing care 975 [23] 2,462 [24]
Total costs for the first year 9,558 14,925
The following years in EUR
(Markov model)
Further hospitalization 2,008 [26] 4,336 [27]
Rehabilitation (admission) 439 [25]
Doctor’s visit/nursing care 974 [23]
Total costs in the following years 3,421 4,336
Bold values are used in the model
Table 5 Cost parameters for subgroups (only myocardial infarction)
NSTEMI/UA STEMI
First year in EUR
Acute hospitalization
(incl. early rehabilitation)
3,793 [22] 5,648 [22]
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of branded clopidogrel is due to ticagrelor being cost-
saving, i.e., dominating, in that sensitivity analysis. Sen-
sitivity analysis for NSTEMI/UA and STEMI were not
provided as the overall results have shown to be very stable
(Fig. 3). The model has shown to be robust against changes
in costs and clinical parameters. In particular, the variation
in the price level of clopidogrel had a strong influence on
the relative results. In order to evaluate the influence of
generic substitution of clopidogrel hydrogenous sulfate
with generic clopidogrel besilate and clopidogrel hydro-
chloride, a separate one-way sensitivity analysis used daily
costs for clopidogrel of EUR 0.35. This resulted in incre-
mental costs for ticagrelor of EUR 560 and an incremental
cost-effectiveness ratio of EUR 3,118 per year of life
gained. By contrast, ticagrelor becomes a dominant strat-
egy when the branded price of clopidogrel is assumed.
The results of the probabilistic sensitivity analysis are
shown in Figs. 3 and 4.
Discussion
The aim of this model was to evaluate the cost-effective-
ness of a combination of ticagrelor and ASA instead of a
combination of clopidogrel and ASA for guideline-rec-
ommended treatment over 12 months post-ACS in a low-
dose ASA cohort for all ACS patients and subtypes
NSTEMI/IA and STEMI. The results of the presented
model are based on clinical events and health-related
quality of life data from the ASA low-dose cohort of the
PLATO study combined with mean cost from published
literature and official tariffs like DRG. They are compa-
rable to published results calculated for the total PLATO
population. Nikolic et al. [14] reported findings that are in
line with the cost-effectiveness of the present study. In that
study, ACS patients treated with ticagrelor and ASA were
projected to increase health-care costs of EUR 362 and
gain a QALY of 0.13 compared with generic clopidogrel
plus ASA. This yields a cost per QALY gained with
ticagrelor of EUR 2,753. The cost per life-year gained was
EUR 2,372. In addition, Theidel et al. [33] reported data,
showing the cost-effectiveness for the treatment of ticagr-
elor in Germany based on overall PLATO results (not
restricted to ASA low dose, no subgroups). In that study the
incremental cost-effectiveness ratio (ICER) for the base
case was EUR 3,274.
Due to the significant proportion of ASS on clinical
effects, it might be expected that the results in this sub-
group were inferior to the ASS group in total PLATO
population. Insofar, our results substantiate the potential
cost-effectiveness of ticagrelor over 12 months compared
to clopidogrel in the country-specific German health care
setting at the current price level—for patients receiving
ticagrelor with ASA low dose and for subgroups NSTEMI/
Table 6 Detailed results of the base case scenario for all subgroups
Ticagrelor Clopidogrel Incremental ICER
Overall ACS patient population B150 mg ASA
Costs in EUR 11,815 11,387 428
Life-years 12.1471 11.9674 0.1796 2,385
QALYs 10.1349 9.9779 0.1570 2,728
NSTEMI/UA
Costs in EUR 12,554 12,049 505
Life-years 11.6438 11.4853 0.1585 3,184
QALYs 9.5356 9.3935 0.1421 3,552
STEMI
Costs EUR 10,453 10,179 274
Life-years 12.7890 12.5968 0.1922 1,426
QALYs 10.9953 10.8341 0.1613 1,700
Fig. 2 Results of univariate
sensitivity analysis for overall
ACS patient population
B150 mg ASA
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UA and STEMI. The model proves to be robust against
changes in various sensitivity analyses. As seen with the
PLATO health economics substudy, the results are mainly
influenced by the commercial prize of clopidogrel that
varies widely between the original drug compound (e.g.,
Plavix) and the generic clopidogrel salts.
The cost-effectiveness of preventive treatments over
short treatment periods is not always easy to determine,
since treatment effects (here the prevention of events fol-
lowing an ACS) extend beyond the on-treatment period.
Accordingly, the design should take into account clinical as
well as monetary aspects over the entire remaining life
span. One advantage of modeling is the opportunity to
compile clinical evidence from different sources as well as
data on the consumption of resources and costs of the
respective health-care system [34]. The detailed results of
the pivotal phase III study over a treatment period of
12 months were fully available for the presented model.
For the subsequent years as a conservative assumption no
relevant differences in efficacy were considered, disre-
garding any potential long-term benefits of ticagrelor. Cost
parameters for Germany were taken from publicly acces-
sible databases and literature. The influence of additional
adverse events is only included via the main efficacy and
benefit parameters as used in the PLATO trial.
Earlier clinical studies showed that there is a correlation
between bleeding and mortality rates as well as recurrent
myocardial infarctions. In a systematic review Cohen et al.
[35] demonstrated that the impact of bleeding on mortality
in ACS patients appears to be confined to the short term.
Studies of long-term mortality consistently indicated that
bleeding was not an independent predictor. However, in-
hospital mortality seems to be strongly related to GRACE
risk score in ACS patients, defined by age and systolic
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blood pressure [36]. Also Fitchett [37] concluded that there
is no causal link between bleeding and increased coronary
artery disease events (e.g., death) after an ACS episode.
Nevertheless, in a retrospective chart review, Bufe et al.
[38] found that bleeding could have an impact on morbidity
and could therefore lead to longer in-hospital stays and to
higher cost of hospitalization in German hospitals. By
using the macro-costing approach, costs of bleeds and
adverse events have already been included in the model.
However, as no information on long-term sequelae is
available this has not been added in the study.
In the literature, various approaches are being discussed
regarding the generation of cost data for model adaptation
[19]. The event costs of the presented model are based on
various publications to ensure the best available evidence
has been included. In this context, each hospitalization is
depicted by the corresponding DRGs [24]. Data on con-
sumption of resources during atherothrombotic events after
hospital discharge have been provided by Bru¨ggenju¨rgen
et al. [25] in a Delphi panel. This study was first performed in
1997 and updated in 2004. All cost data that were used for
the cost calculation were taken from publicly accessible
documents and tariff catalogues. In terms of cardiological
rehabilitation the publication of Zeidler et al. [27] a claims
data analysis of the statutory health insurance data, was
additionally used. Complete results from the Delphi panel
were used in a sensitivity analysis. Cost data describing
resource use for stroke care were alternatively taken from of
a German health care services research study. Here, the
authors explored in great detail the resource use of stroke
patients (n = 558) over a period of 12 months yielding
direct and indirect cost estimates [26]. In addition, with data
from the Erlangen Stroke Registry [39] another data source
was taken into consideration in a sensitivity analysis.
Regarding the cost data for subsequent years, an extensive
research of the literature was performed. Lamotte et al. [28]
used data from Federal Statistics with regard to rehospital-
ization after myocardial infarction. Winter et al. [29] eval-
uated the long-term costs after a stroke in a highly detailed
cost of illness study. Although that study is limited by its
small sample size (n = 151), only minor deviations with
respect to direct costs are suggested from the data of the
Erlangen Stroke Registry. The cost of ‘‘death’’ has been
calculated using DRG information and data from Federal
Statistics. Since the therapy in PLATO was started following
an ACS event with the aim to prevent MIs, strokes and
associated death, no additional costs were incorporated for
patients without additional events as observed in PLATO
except, of course, for costs of medication. This assumption
was tested in sensitivity analyses adding appropriate addi-
tional costs to determine the influence of these costs.
Observed utility values from the PLATO study are in the
range of reported values for ischemic heart diseases
measured by EQ-5D in different published studies. An
evaluation of data from the MONICA registry in Germany
[40] reports the quality of life several years after a myo-
cardial infarction relative to the general population.
Observed values in the registry population were similar to
those observed in PLATO. No specific data for quality of
life in German ACS population exist. A recently published
review showed that published values are heterogenic, but
the EQ-5D seems to be an appropriate questionnaire to
measure the quality of life in cardiovascular diseases.
Overall response to the questionnaire in the PLATO study
was \70 % of the ITT population. There were no signifi-
cant differences in quality of life between ticagrelor and
clopidogrel reported from the trial [41, 42].
The main limiting factor of the model is the restriction
to the PLATO data as its main source on treatment effects,
and it shares the limitations of this trial, e.g., regarding
specific subgroups and the duration of the recommended
therapy. Our analysis may not apply to patients who were
excluded from the trial. Beyond the PLATO trial, no real-
world evidence could be generated. Duration of treatment
and observed effect data are limited to the first year.
Modeling the costs and health outcomes for subsequent
years is based on assumptions. Mortality rates during the
acute ACS phase will most likely continue to decline in the
future, but the prevalence of patients with a prior MI and
stable coronary artery disease will continue to increase.
[43] To be able to distinguish different ACS risk groups
and assign the appropriate long-term mortality, future
model revisions should also try to estimate the cost-effec-
tiveness of ticagrelor versus clopidogrel separately for
other subgroups [44, 45].
To simplify the model, no subsequent events, therapy
switches or various treatment durations were taken into
consideration. These could, however, be relevant in clinical
practice.
Furthermore, all cost data are based on literature
research or official databases (e.g., DRG Browser) with the
same mean annual cost per health state regardless of initial
intervention. To obtain more detailed data regarding
resource use of each treatment strategy and associated cost
or benefits, a claims data analysis could support the model
in the future with data from a real-world setting, when
ticagrelor has a greater market penetration. It would also
give the opportunity to observe changes in clinical practice.
This model was set up specifically to evaluate the
German context. Even in other countries with similar
health-care systems, the results of this study may not apply.
When interpreting the implications of this study, the reader
is advised to keep in mind that this is a modeling study that
combines PLATO data and assumptions on long-term
outcomes that are reasonable in the absence of hard data. In
a decision context, the uncertainty related to these
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modeling assumptions must be balanced against the pos-
sibility of substantiating the model with actual data
obtained in the German setting and over a longer time
horizon.
There are no published willingness-to-pay threshold
values for the cost-effectiveness of therapy in Germany.
While no universal threshold for cost-effectiveness exists, a
cost per additional life-year gained or quality-adjusted life-
year (QALY) in the range of EUR 25,000 (USD 33,000) to
EUR 38,000 (USD 50,000) is generally considered as cost-
effective [46, 47]. Applying this generally accepted
benchmark, treatment with ticagrelor would be considered
a cost-effective option in Germany with costs per life-year
gained of EUR 2,385 in the base case scenario and EUR
3,118 per life-year gained when less expensive generic
clopidogrel compounds are being used. With a presumed
QALY threshold of EUR 25,000/EUR 38,000 the proba-
bility of being cost-effective would be 99.98 %/99.99 %
for the overall ACS population, 99.24 %/99.50 % for
NSTEMI/UA, and 99.57 %/99.66 % for STEMI, respec-
tively. But results may not fully capture the German setting
because not all required inputs were available by publicly
accessible literature and databases.
In conclusion, treatment of ACS with ticagrelor instead
of clopidogrel over a time period of 12 months should offer
a cost-effective therapeutic option in the context of the
German health care system, even when considering the
lower cost of generic clopidogrel. In addition, our findings
are consistent with the cost-effectiveness of ticagrelor as
seen in the international PLATO substudy.
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